Page:United States Statutes at Large Volume 124.djvu/1008

 124 STAT. 982 PUBLIC LAW 111–148—MAR. 23, 2010 ‘‘(6) COMPENSATION AND TRAVEL EXPENSES.— ‘‘(A) COMPENSATION.—Members shall receive com- pensation at a rate to be fixed by the Chairperson but not to exceed a rate equal to the daily equivalent of the annual rate of basic pay prescribed for level IV of the Executive Schedule under section 5315 of title 5, United States Code, for each day (including travel time) during which the member is engaged in the performance of the duties of the Board. All members of the Board who are officers or employees of the United States shall serve with- out compensation in addition to that received for their services as officers or employees of the United States. ‘‘(B) TRAVEL EXPENSES.—Members of the Board shall be allowed travel expenses, including per diem in lieu of subsistence, at rates authorized for persons employed intermittently by the Federal Government under section 5703(b) of title 5, United States Code, while away from their homes or regular places of business in the perform- ance of services for the Board. ‘‘(e) GRANT PROGRAM.— ‘‘(1) SUPPORTING INNOVATION.—To carry out the purposes described in this section, the Director of NIH shall award contracts, grants, or cooperative agreements to the entities described in paragraph (2), to— ‘‘(A) promote innovation in technologies supporting the advanced research and development and production of high need cures, including through the development of medical products and behavioral therapies. ‘‘(B) accelerate the development of high need cures, including through the development of medical products, behavioral therapies, and biomarkers that demonstrate the safety or effectiveness of medical products; or ‘‘(C) help the award recipient establish protocols that comply with Food and Drug Administration standards and otherwise permit the recipient to meet regulatory require- ments at all stages of development, manufacturing, review, approval, and safety surveillance of a medical product. ‘‘(2) ELIGIBLE ENTITIES.—To receive assistance under para- graph (1), an entity shall— ‘‘(A) be a public or private entity, which may include a private or public research institution, an institution of higher education, a medical center, a biotechnology com- pany, a pharmaceutical company, a disease advocacy organization, a patient advocacy organization, or an aca- demic research institution; ‘‘(B) submit an application containing— ‘‘(i) a detailed description of the project for which the entity seeks such grant or contract; ‘‘(ii) a timetable for such project; ‘‘(iii) an assurance that the entity will submit— ‘‘(I) interim reports describing the entity’s— ‘‘(aa) progress in carrying out the project; and ‘‘(bb) compliance with all provisions of this section and conditions of receipt of such grant or contract; and Contracts.